# Checkpoint Surgical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/checkpoint-surgical

- Industry: Medical Devices & Equipment
- Headquarters: Independence, US
- Website: www.checkpointsurgical.com
- Total disclosed funding: $13M
- Latest round: Series B (Sep 28, 2018)
- Investors on record: 4

## About

Checkpoint Surgical, LLC is a US-based company specializing in innovative solutions for peripheral nerve surgery, emphasizing the protection and repair of nerves during surgical procedures.Founded in 2010 and headquartered in Independence, US, Checkpoint Surgical, LLC focuses on advanced medical devices for nerve surgery. The company has completed 10 deals, with the latest funding round occurring on May 27, 2021. This round raised USD 16.00 mn, led by RC Capital and included investors such as First Analysis, JumpStart, and Mutual Capital Partners. The company was established by Leonard Cosentino, who has a history in the medical device sector. The latest funding will support the company’s growth initiatives.Checkpoint Surgical specializes in innovative solutions for peripheral nerve surgery, focusing on nerve protection and repair. The company's core product offerings include the CHECKPOINT® Stimulators, designed for safe, prolonged stimulation to enhance nerve response during surgeries. Additionally, the CHECKPOINT ACMShield™ serves as a dehydrated placental membrane allograft, providing a protective barrier in nerve and tendon repairs. The CHECKPOINT EDGE® Nerve Cutting Kit is engineered to maintain fascicular group alignment during nerve cutting, targeting neurosurgeons, orthopedic surgeons, and plastic surgeons across the US, Europe, and Asia.Checkpoint Surgical operates primarily through direct sales to healthcare facilities, focusing on B2B transactions with hospitals and surgical centers. The revenue generation is centered on the sale of specialized medical devices like the CHECKPOINT® Stimulators and CHECKPOINT EDGE® Nerve Cutting Kit, allowing customers to order in bulk to meet surgical demands. The pricing structure reflects the premium nature of these products, which are essential for complex nerve surgeries, contributing to the firm's financial stability and growth in the surgical device market.Following the successful USD 16.00 mn funding round in May 2021, Checkpoint Surgical plans to expand its team and support the launch of new products, including the recently acquired NeuroShield. The company aims to penetrate new markets, specifically targeting regions in Europe and Asia by 2023. The recent funding will assist in research and development activities as well as product launches to enhance their offerings in the nerve surgery domain.

## Funding rounds

- Series B, Sep 28, 2018, $8.8M — First Analysis, JumpStart, Mutual Capital Partners
- Series B, Feb 9, 2012, $1.7M — NDI Medical
- Series B, Dec 1, 2011, $1.7M — NDI Medical
- Series A, Nov 10, 2009, $1.1M — JumpStart

## Investors

- JumpStart (https://capitalatlas.ai/funds/jumpstart) — Series A, Series B
- NDI Medical (https://capitalatlas.ai/funds/ndi-medical) — Series B
- First Analysis (https://capitalatlas.ai/funds/first-analysis) — Series B
- Mutual Capital Partners (https://capitalatlas.ai/funds/mutual-capital-partners) — Series B